Advertisements

Cefamax

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Cefamax

What is Cefamax? An Overview

Cefamax is a brand name for the synthetic, prescription-only medicine containing the active ingredient Cefepime. It is a powerful antimicrobial agent used in hospital settings for serious bacterial infections.

Quick Facts

Property Description
Active ingredient Cefepime (INN)
Form Sterile, lyophilized powder
Pharmacological class beta-Lactam Antibiotic
Generation Fourth-generation cephalosporin
Common use (General) Systemic anti-infective therapy
Origin Semi-synthetic

What Type of Medicine is Cefamax?

Cefamax is a high-level beta-Lactam antibiotic classified as a fourth-generation cephalosporin. This advanced classification is key to its therapeutic role: Cefepime is designed with structural modifications that allow it to be more stable against many bacterial enzymes called beta-lactamases. This stability increases its reliability and broadens its scope of activity against a wide range of susceptible Gram-positive and Gram-negative pathogens.


Composition and Pharmaceutical Form

The medicine is supplied as a sterile, lyophilized powder in a vial, which must be reconstituted into a liquid solution before administration. This preparation method is necessary because Cefepime is intended solely for parenteral administration—delivered directly into a vein or muscle—for systemic action throughout the body. The powder is a single product based on the active substance Cefepime along with the excipient L-Arginine, included to maintain chemical stability and the correct pH for use.


High-Level Purpose

The core function of Cefepime is to act as a bactericidal agent, meaning it actively kills susceptible bacteria rather than just inhibiting their growth. It achieves this by disrupting the synthesis of the bacterial cell wall, a characteristic mechanism of the beta-Lactam class. The overall goal is to eliminate the infectious organism, making Cefamax a critical, potent option used when fighting serious, typically hospitalized infections where broad and reliable coverage against unknown or resistant bacteria is necessary.

Regulatory References

  1. Cefepime - StatPearls (NIH)
  2. Cefepime Injection: MedlinePlus Drug Information
Advertisements

What side effects are possible with Cefamax?

Cefamax, which contains the active substance Cefepime, has an official safety profile organized according to authoritative regulatory classifications of adverse reactions and systemic effects. The documentation groups potential effects by frequency and the body system affected (System-Organ-Class).

Frequency-Classified Adverse Reactions

Adverse reactions observed in clinical trials are categorized by their documented rate of occurrence:

  • Common (occurring in ge 1% of patients): Phlebitis at the injection site, rash, diarrhea, nausea, vomiting, headache, positive Direct Coombs' Test, and transient increases in liver enzymes (ALT/AST).
  • Uncommon (0.1% to <1%): Colitis, oral candidiasis, urticaria, and changes in blood cell counts (leukopenia, neutropenia, thrombocytopenia).

Serious Adverse Reactions and Safety Constraints

The official labeling highlights the potential for serious or life-threatening events, which include severe Hypersensitivity reactions, sometimes resulting in anaphylaxis. The label also documents the risk of severe Neurotoxicity, such as encephalopathy, myoclonus, and seizures (including nonconvulsive status epilepticus), particularly reported in the postmarketing setting. Potentially fatal Clostridioides difficile-associated diarrhea (CDAD) is also a documented risk.

The regulatory documentation emphasizes specific Safety Constraints related to kidney function. The most serious cases of neurotoxicity are primarily associated with patients who have impaired renal function (including older adults) and did not receive appropriate dosage adjustments. Additionally, prolonged use may lead to the overgrowth of nonsusceptible organisms, a concept known as superinfection.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help


Documented Overdose Manifestations

Overdose of Cefamax (Cefepime) is primarily documented by the onset of severe neurotoxicity. Official prescribing information lists clinical manifestations that include encephalopathy, which is often characterized by confusion, hallucinations, stupor, and coma. Other severe neurological signs that may occur are myoclonus (muscle spasms) and seizures, including nonconvulsive status epilepticus. These severe, life-threatening outcomes are typically associated with drug accumulation.


Regulator-Mandated Emergency Actions

If any signs of neurotoxicity are noted, the official labeling requires the immediate discontinuation of Cefamax. Patients displaying severe symptoms, such as the onset of seizures or a significant decrease in responsiveness, must seek immediate medical attention or emergency medical treatment.


Management and Population Considerations

Management of an overdose relies on symptomatic and supportive measures. There is no specific antidote known for Cefepime toxicity. Hemodialysis is the documented procedural intervention that can significantly aid in removing the drug from the body. The risk of these severe overdose manifestations is explicitly heightened in patients with impaired renal function who have not received appropriate dosage adjustments, with geriatric patients being noted as a high-risk group.

Advertisements

Therapeutic Uses of Cefamax

Quick Facts: Uses of Cefamax

  • May address infections affecting the lower respiratory tract.
  • May provide coverage for skin and soft tissue infections.
  • Is utilized to help manage infections of the genito-urinary tract.
  • Is an option for treating certain bone and joint infections.

Cefamax is a prescription medication utilized in the management of bacterial infections. It is generally indicated for treating susceptible strains of bacteria that may affect multiple areas of the body. These therapeutic domains include infections of the lower respiratory tract, such as certain types of pneumonia, and conditions impacting the genito-urinary tract.

The medication may also provide coverage for infections within the central nervous system, intra-abdominal infections, and certain bone and joint infections. Additionally, Cefamax is an option for the treatment of septicemia, gynecologic infections, and complicated infections of the skin and soft tissues. It may be used in a hospital setting for specific uses, such as for surgical prophylaxis to help prevent infections before a procedure.

Regulatory References

  1. NIH MedlinePlus guidance
Advertisements

Eligibility and Restrictions for Use

Cefamax (Cefalexin) is an antibiotic whose use is strictly governed by patient eligibility and contraindication rules, as defined by regulatory authorities.

Contraindicated Populations

Cefamax is formally contraindicated in individuals with a known allergy or hypersensitivity to the cephalosporin class of antibiotics. Because of the potential for cross-sensitivity, special caution is also required for patients with a history of allergy to penicillin or other beta-lactam antibiotics.

Special Care and Restrictions

Use is allowed but requires special consideration in specific patient groups:

  • Impaired Renal Function: Patients with significantly reduced kidney function (impaired renal function) must have the dosage carefully adjusted and lowered, as the drug is primarily cleared by the kidneys.
  • Gastrointestinal Disease: Caution is necessary for patients with a history of gastrointestinal disease, particularly colitis.
  • Pregnancy and Lactation: Although clinical studies have not shown evidence of harm, it should be used with caution during pregnancy, particularly the early months. Use in nursing mothers also requires caution as the drug is excreted in breast milk.

Age-Related Eligibility

Cefalexin is approved for use in adults and children. The specific dosage for the pediatric population (including infants) is determined by body weight and age.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Cefamax (Cefepime) is defined by mandatory co-administration restrictions and specific risks related to its primary renal elimination pathway, as documented in regulatory sources.


Contraindicated Combinations and Class Risks

Co-administration of Cefamax is strictly contraindicated in individuals with a documented history of immediate hypersensitivity to Cefepime itself or to the cephalosporin, penicillin, or other beta-lactam antibacterial classes.


Clinically Significant Co-administration Risks

Cefepime co-administration with other medicines that possess similar organ toxicities requires specific regulatory oversight.

  • Aminoglycoside Antibiotics and Potent Diuretics (such as Furosemide) are associated with an increased potential for nephrotoxicity and ototoxicity. Official regulatory information mandates renal function monitoring when Cefamax is co-administered with these product classes.
  • Substances that inhibit renal tubular secretion can increase and prolong the serum concentration of Cefepime by reducing its total clearance.

Population and Product Constraints

Official labeling outlines critical constraints based on patient condition and non-medicinal products:

  • Impaired Renal Function: Patients with reduced kidney function (CrCL le 60 mL/min) are at risk of drug accumulation. Unadjusted Cefepime dosages lead to prolonged high serum concentrations, which increases the documented risk of neurotoxicity (including encephalopathy and seizures).
  • Laboratory Tests: Cefepime administration may result in a false-positive reaction for glucose in the urine when utilizing copper reduction tests (e.g., Clinitest tablets).
Advertisements

Mechanism of Action

Cefepime, the active ingredient in Cefamax, acts through the covalent blockade of bacterial cell wall assembly. The molecule achieves this by targeting and irreversibly binding to Penicillin-Binding Proteins (PBPs) (specifically PBP1a, PBP2, and PBP3), which are essential enzymes located in the bacterial cytoplasmic membrane. This interaction inhibits the transpeptidation step, which is the final process of cross-linking the peptidoglycan strands necessary for structural integrity. The failure to complete the rigid cell wall compromises the bacterium's ability to withstand internal osmotic pressure, triggering the autolytic system and leading to cell lysis (rupture) and a bactericidal effect. A unique mechanistic characteristic is Cefepime's inherent structural stability against hydrolysis by many defensive bacterial enzymes, particularly AmpC beta-lactamases. This stability allows the drug to access its PBP targets consistently, supporting the progression of the bactericidal cascade against pathogens that utilize these enzymatic defenses.

Advertisements

Dosage and Administration Information

Cefamax is a prescription medication administered exclusively through parenteral routes and is typically used within a supervised clinical environment.

Administration Routes and Preparation

The medicine is supplied as a sterile, lyophilized powder that requires reconstitution and subsequent dilution before use. The primary and most common route is intravenous (IV) infusion, which is administered over a period of approximately 30 minutes. A secondary route, intramuscular (IM) injection, is officially reserved for treating mild to moderate uncomplicated or complicated urinary tract infections. For certain conditions, such as complicated intra-abdominal infections, Cefamax is administered in combination with metronidazole.

Standard Dosing Regimens

Dosing is determined by the severity of the infection and is given on a regular schedule. The standard frequency is either every 12 hours (q12h) for most moderate infections or every 8 hours (q8h) for severe, life-threatening conditions like febrile neutropenia. Doses typically range from 0.5 g to 2 g per administration, with the maximum dose reaching 2 g every 8 hours. The full course of therapy typically lasts 7 to 14 days, depending on the clinical scenario.

Population-Specific Use Constraints

For patients with renal impairment, a mandatory dose adjustment is required. The maintenance dose must be lowered, or the time interval between doses must be extended, based on the patient's estimated Creatinine Clearance. Pediatric patients (aged 2 months to 16 years) receive a weight-based dose of 50 mg/kg per administration.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section describes the clinical studies conducted on Cefamax, the selective COX-2 inhibitor. Research has evaluated its potential to lessen inflammation and pain in conditions like osteoarthritis (OA) and rheumatoid arthritis (RA).


Study Focus and Population

  • Study Population: In research, short-term use (up to 4 weeks) was evaluated in study participants who were generally healthy adults or those with mild-to-moderate arthritis.
  • Research Focus: Research was conducted to evaluate its interaction with the inflammatory process associated with joint stiffness.

Clinical Trials in Osteoarthritis (OA)

Clinical trials focusing on OA observed lower average joint pain scores and some participant-reported functional changes across a range of doses.

  • Trial Outcomes: In placebo-controlled trials, differences in pain scores between the group receiving the study drug and the placebo group were observed.
  • Onset of Action: Research explored the onset of action, with some participants noting a change in symptoms shortly after starting the treatment. In some trials, a positive change in symptoms was reported by certain participants during the first week.
  • Comparative Studies: Comparison trials assessed the differences in outcomes between the study drug and standard NSAIDs. These studies examined differences in measured metrics and the incidence of gastrointestinal events.

Extended Research and Safety Profile

Long-term data examined whether the reported symptom changes were maintained in studies lasting 6 months to 1 year, though the evidence remains limited in studies exceeding one year.

  • Gastrointestinal Profile: Studies assessed the drug's gastrointestinal profile against that of traditional, non-selective NSAIDs.
  • Cardiovascular Status: Research protocols excluded individuals with pre-existing heart conditions. Further study is required to fully characterize potential cardiovascular considerations.

Key Studies & References ACR Guideline for the Treatment of Rheumatoid Arthritis (Informs combination therapy use)

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Cefamax (FAQ)

Q: How quickly does Cefamax usually start working to improve symptoms?

Studies have examined the onset of effect, with some participants in clinical trials noting changes in symptoms shortly after starting the treatment. Research also indicated that some participants reported a positive change in symptoms within the first week of therapy.

Q: Is Cefamax safe to use for patients with kidney problems?

Patients with reduced kidney function are required to have a mandatory dose adjustment. This is necessary because the drug is primarily cleared by the kidneys, and an unadjusted dose can lead to accumulation, which increases the documented risk of neurotoxicity.

Q: Can Cefamax cause diarrhea, and what does it mean if the diarrhea is severe?

Diarrhea is listed as a common adverse reaction in official product information. If diarrhea becomes severe, it can be a sign of a more serious, potentially fatal complication called Clostridioides difficile-associated diarrhea (CDAD), which is a documented risk associated with the medication.

Q: What should I discuss with my healthcare provider before starting Cefamax?

It is important to discuss certain patient factors with a healthcare provider based on official safety constraints. Key topics include any history of allergy to Cefamax, cephalosporins, or penicillin. The official safety constraints indicate that pre-existing kidney problems or a history of gastrointestinal diseases, particularly colitis, are relevant factors for discussion.

Q: Is Cefamax considered a broad-spectrum antibiotic?

Official drug descriptions define Cefamax, which contains the active ingredient Cefepime, as a fourth-generation cephalosporin. This classification is associated with broad-spectrum activity against a wide range of susceptible Gram-positive and Gram-negative bacteria.

Q: Can Cefamax affect the reliability of birth control pills?

Regulatory discussions have noted a theoretical possibility that broad-spectrum antibiotics may slightly lower the systemic levels of the estrogen component found in hormonal contraceptives. However, the risk of failure is generally considered small.

Q: Is it normal to feel tired or dizzy while taking Cefamax?

The full list of documented adverse effects for this medication includes a general feeling of tiredness or weakness and dizziness. These effects are documented as having a rare or unknown frequency in the official safety profile.

Q: How is Cefamax different from Amoxicillin or other common antibiotics?

Cefamax is a fourth-generation cephalosporin, making it structurally different from penicillin-class antibiotics like Amoxicillin. Regulatory documents note its enhanced stability against certain bacterial defense enzymes (beta-lactamases), which supports its therapeutic range.

Q: What are the official recommendations for Cefamax use during pregnancy?

Cefamax is classified under US FDA Pregnancy Category B and AU TGA Category B1. The drug is generally recommended for use during pregnancy only if the potential benefits are considered to clearly outweigh any potential risks to the fetus.

Q: Does Cefamax pass into breast milk, and what are the general warnings for breastfeeding mothers?

Official information confirms that the active substance, Cefepime, is excreted into human milk. Caution is advised for nursing mothers, and the official documentation indicates that a healthcare professional must consider whether the potential benefit to the mother justifies the potential risk to the nursing infant before use.

Q: Can Cefamax cause yeast infections, and is that a common concern?

The development of oral candidiasis (a type of yeast infection in the mouth) is a documented, uncommon adverse reaction. Other signs that may be related to fungal overgrowth, such as vaginal discharge or itching, have also been reported with unknown incidence.

Q: Does Cefamax affect blood sugar levels or interfere with diabetes medication like Metformin?

Official documentation states that Cefamax is not known to directly affect blood sugar levels or interfere with glucose metabolism. However, it may cause a false-positive reaction for glucose when using certain urine tests that rely on copper reduction methods.

Q: Are there any reported interactions between Cefamax and gout medications like probenecid?

Official documents note that medicines that inhibit renal tubular secretion may increase and prolong the concentration of Cefamax in the blood. This means the drug could stay in the body longer than expected if taken with such substances.

Q: Do older patients need a different dosage or special considerations for Cefamax?

Older adults are noted as a population at risk for drug accumulation and neurotoxicity. This risk is primarily due to underlying reduced kidney function, which necessitates a mandatory dose adjustment.

Q: Can Cefamax interfere with the results of certain lab or blood tests?

Yes, the drug is known to cause a false-positive reaction for glucose in the urine when using copper reduction tests. It may also result in a positive Direct Coombs' Test or a false-positive beta-D-glucan test.

Q: Can Cefamax be used to treat skin infections?

Regulatory documents confirm that Cefamax is indicated for the treatment of uncomplicated skin and skin structure infections. It is approved for use against infections caused by susceptible microorganisms.

Q: Is Cefamax used for respiratory tract infections?

Official labeling confirms that Cefamax is indicated for the treatment of moderate to severe pneumonia, which is a type of infection affecting the respiratory tract.

Q: Are there different forms of Cefamax (e.g., capsule, tablet, syrup)?

The drug is supplied as a sterile, lyophilized powder in a vial, which is prepared for intravenous (IV) or intramuscular (IM) administration only. There are no oral forms such as capsules, tablets, or syrups listed in the regulatory documents.

Q: What is the research evidence summary for Cefamax's effectiveness?

Clinical trials and regulatory approval support its use for systemic anti-infective therapy against serious bacterial infections. Indications supported by evidence include pneumonia, complicated urinary tract infections, and complicated intra-abdominal infections (in combination with metronidazole).

Q: What is the risk of Cefamax causing antibiotic resistance if used incorrectly?

Official warnings note that using the medication when there is no proven or strongly suspected bacterial infection increases the risk. This practice can contribute to the development of drug-resistant bacteria.

Q: What is the difference between a common side effect and a serious side effect of Cefamax?

Regulatory documents classify adverse reactions based on their documented frequency in clinical trials (e.g., common or uncommon). Certain events, such as neurotoxicity (nerve damage) and severe hypersensitivity (allergic reaction), are specifically highlighted as serious adverse reactions.

Q: Why might a doctor prescribe Cefamax over another antibiotic for a certain infection?

Regulatory information and mechanism of action studies show Cefamax has structural stability against certain bacterial defense enzymes (beta-lactamases). This feature supports its therapeutic use against a wide range of susceptible bacteria, including some that may be resistant to older antibiotics.

Q: What is the chance of Cefamax causing confusion or dizziness that impacts driving?

Confusion and dizziness are documented as possible effects, particularly in patients who have accumulated the drug due to unadjusted dosing and kidney problems. These effects are related to the serious documented risk of neurotoxicity.

Q: What kind of studies have been performed to determine the safety of Cefamax?

The official safety profile is based on data collected from controlled clinical trials that assess adverse reactions in patients. It is also informed by ongoing monitoring and analysis of post-marketing surveillance reports.

Q: Can Cefamax be prescribed for urinary tract infections (UTIs)?

Yes, official indications for Cefamax include the treatment of both uncomplicated and complicated urinary tract infections. In some cases, the drug may be administered via intramuscular injection for mild to moderate UTIs.

Q: Is Cefamax safe for long-term use, or only for short treatment periods?

The typical course of therapy is short, usually lasting 7 to 14 days. Official warnings state that prolonged use may increase the risk of the overgrowth of nonsusceptible organisms, a condition known as superinfection.

Q: Why might Cefamax cause stomach discomfort or indigestion?

The adverse reaction profile for Cefamax lists nausea and vomiting as common effects reported by patients in clinical trials. These effects are the likely documented cause of the more general terms like stomach discomfort or indigestion.

Advertisements

How should Cefamax be stored and disposed of?

How to Store and Dispose of Cefamax (Cefepime)

The unreconstituted powder of Cefamax must be stored in its original container at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), and protected from light.

Stability and Handling

The reconstituted solution has specific stability limits: it is stable for up to 7 days when refrigerated (2 C to 8 C) or for 24 hours at room temperature.

  • Do not freeze the solution.
  • The solution must be visually inspected for particulate matter before use.
  • The medicine must be kept out of the sight and reach of children.

Disposal

Unused or expired product should not be disposed of via wastewater or household trash. Disposal must be completed according to local requirements for pharmaceutical waste or by using an authorized drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cefamax found in:

A-Z Index: